A Phase 2 interventional study of SRK-015 in Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 and Spinal Muscular Atrophy Type 2, sponsored by Scholar Rock, Inc.. Completed at 16 sites in 4 countries. Open to participants aged 2 Years to 21 Years. Per ClinicalTrials.gov, last updated 2024-12-02.
Sponsored by Scholar Rock, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Spinal Muscular Atrophies of Childhood with a site in United States — 3 open to participants now, 7 under way, 2 of them phase 3. Spinal Muscular Atrophies of Childhood · United States.
Among the 23 studies in Spinal Muscular Atrophies of Childhood with a site in United States, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2019, is one of 2 in phase 2, and was the 11th registered.
61 studies on the registry are indexed under Spinal Muscular Atrophies of Childhood; 18 are open to participants now.
Browse Spinal Muscular Atrophies of Childhood studies →3 of the 23 studies in Spinal Muscular Atrophies of Childhood with a site in United States are open now. Recruiting first, the newest first:
Jacqueline Montes · Sites in United States
Ages 8–50
Scholar Rock, Inc. · Sites in United States, Belgium, France and 4 more countries
Ages up to 2
Columbia University · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Spinal Muscular Atrophies of Childhood studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 2 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 4
First in 1986; this study’s year is marked. 2 started in 2019.
This study's enrollment of 58 is above the median of 15 across 41 interventional studies indexed under Spinal Muscular Atrophies of Childhood.
Median enrollment 40 across the 13 interventional studies, 88 across the 10 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 23 have an industry lead sponsor. The 10 most frequent:
Scholar Rock, Inc. is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Scholar Rock, Inc. has 4 studies filed under Spinal Muscular Atrophies of Childhood — fewer than ten, so there is no comparison to draw.
1 of the studies in Spinal Muscular Atrophies of Childhood with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400198Jacqueline MontesGait and Bone Health in SMA | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Spinal Muscular Atrophies of Childhood with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The TOPAZ study will assess the safety and efficacy of SRK-015 in later-onset Spinal Muscular Atrophy (SMA Type 2 and Type 3) in pediatric and adult patients.
61 studies on the registry are indexed under Spinal Muscular Atrophies of Childhood; 18 are open to participants now.
This study's enrollment of 58 is above the median of 15 across 41 interventional studies indexed under Spinal Muscular Atrophies of Childhood.
Browse Spinal Muscular Atrophies of Childhood studies →Scholar Rock, Inc. is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Compared within Spinal Muscular Atrophies of Childhood, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Muscular Atrophy, Spinal. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Receiving the same background SMA therapy (e.g., on an approved survival motor neuron (SMN) upregulator therapy such as nusinersen, or not on any SMA therapy) for at least 6 months prior to screening and anticipated to remain on that therapy throughout the duration of the study.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ambulatory Type 3 SMA
Biological: SRK-015
Type 2 SMA / Non-Ambulatory Type 3 SMA
Biological: SRK-015
Type 2 SMA
Biological: SRK-015
SRK-015 is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that binds to human pro/latent myostatin with high affinity. SRK-015 will be administered every 4 weeks by intravenous infusion.
Cohort 1: Change From Baseline in the Revised Hammersmith Scale (RHS) Total Score at Day 364 (Visit 15) [Month 12]
The Revised Hammersmith Scale (RHS) is a 36 item clinical assessment of physical abilities in patients with Type 2 SMA and ambulatory or nonambulatory patients with Type 3 SMA. For the ambulatory Type 3 patients 5-21 years of age in Cohort 1 (N=23), the primary endpoint was the change from baseline in RHS total score at month 12. The RHS has a minimum achievable score of 0 and a maximum achievable score of 69. The RHS includes 33 items that are graded on a scale of 0, 1, 2, where 0 denotes the lowest level and 2 denotes the highest level of ability/function. The remaining 3 items are scored 0 or 1, where 0 denotes an inability and 1 denotes an ability to achieve. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement.
Time frame: Baseline up to 12 months
Cohort 2 and Cohort 3: Change From Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) Total Score at Day 364 (Visit 15) [Month 12]
Cohort 2: For the nonambulatory Type 2 and Type 3 patients 5-21 years of age in Cohort 2 (N=15), the primary efficacy endpoint was the change from baseline in HFMSE total score at month 12. Cohort 3: For the nonambulatory Type 2 patients ≥2 years of age in Cohort 3 (N=20), the primary efficacy endpoint was the change from baseline in HFMSE total score at month 12. The Hammersmith Functional Motor Scale Expanded (HFMSE) assesses the physical abilities of patients with Type 2 and Type 3 SMA comprises 33 items graded on a scale of 0, 1, or 2, where 0 denotes unable, 1 denotes performed with modification or adaptation, and 2 denotes performed without modification or adaptation.
Time frame: Baseline up to 12 months
Cohort 1:Change From Baseline in the Revised Hammersmith Scale (RHS) Total Score at Other Prespecified Timepoints
The Revised Hammersmith Scale (RHS) is a 36 item clinical assessment of physical abilities in patients with Type 2 SMA and ambulatory or nonambulatory patients with Type 3 SMA; it has a maximum achievable score of 69. The RHS includes 33 items that are graded on a scale of 0, 1, 2, where 0 denotes the lowest level and 2 denotes the highest level of ability/function. The remaining 3 items are scored 0 or 1, where 0 denotes an inability and 1 denotes an ability to achieve.
Time frame: Baseline to 12 months
Cohort 1: Proportion of Patients Achieving Various Magnitudes of Change in RHS Score From Baseline
The Revised Hammersmith Scale (RHS) is a 36 item clinical assessment of physical abilities in patients with Type 2 SMA and ambulatory or nonambulatory patients with Type 3 SMA; it has a maximum achievable score of 69. The RHS includes 33 items that are graded on a scale of 0, 1, 2, where 0 denotes the lowest level and 2 denotes the highest level of ability/function. The remaining 3 items are scored 0 or 1, where 0 denotes an inability and 1 denotes an ability to achieve.
Time frame: Baseline to 12 months
Cohort 1: Change From Baseline in 6-Minute Walk Test (6MWT)
6-Minute Walk Test The 6-Minute Walk Test (6MWT) is an assessment of exercise capacity and fatigue used for ambulatory patients with later-onset SMA who are directed to walk along a 25 meter course as fast as possible over 6 minutes.
Time frame: Baseline to 12 months
Cohort 1: Change From Baseline in 30-Second Sit-to-Stand
The 30-Second Sit-to-Stand Test is an assessment of functional lower-limb strength that measures the maximal number of times a patient can transition from sitting to standing in 30 seconds.
Time frame: Baseline to 12 months
Cohort 1: Change From Baseline in 10-Meter Walk/Run (From RHS)
The 10 Meter Walk/Run test is an enhanced function of the RHS used for ambulatory patients with Type 3 SMA. It is a measure of the time taken to walk/run 10 meters. The time to perform is summarized only for patients able to complete the RHS 10-meter walk/run item.
Time frame: Baseline to 12 months
Cohort 1: Change From Baseline in Timed Rise From Floor (From RHS)
The timed rise from floor test is an enhanced function of the RHS used for ambulatory patients with Type 3 SMA. It is a measure of the time taken to rise to standing from the floor. The time to rise from floor is summarized only for patients able to complete the RHS rise from floor item.
Time frame: Baseline to 12 months
Cohort 2 &3: Change From Baseline in HFMSE Total Score at Other Prespecified Timepoints
The Hammersmith Functional Motor Scale Expanded (HFMSE) assesses the physical abilities of patients with Type 2 and Type 3 SMA comprises 33 items graded on a scale of 0, 1, or 2, where 0 denotes unable, 1 denotes performed with modification or adaptation, and 2 denotes performed without modification or adaptation.
Time frame: Baseline to 12 months
Cohort 2 & 3: Proportion of Patients Achieving Various Magnitudes of Change in HFMSE Score From Baseline
The Hammersmith Functional Motor Scale Expanded (HFMSE) assesses the physical abilities of patients with Type 2 and Type 3 SMA comprises 33 items graded on a scale of 0, 1, or 2, where 0 denotes unable, 1 denotes performed with modification or adaptation, and 2 denotes performed without modification or adaptation.
Time frame: Baseline to 12 months
Cohort 2 & 3: Change in Baseline in Revised Upper Limb Module (RULM) Total Score
The RULM is a 20 item assessment of upper limb function in nonambulatory patients with SMA that was performed for patients who were 30 months of age or older at baseline. The 19 scored items assess functions that relate to everyday life, such as pressing a button and picking up a token; these items are scored 0, 1, or 2, where 0 denotes unable, 1 denotes able with modification, and 2 denotes able with no modification. The maximum score achievable is 37.
Time frame: Baseline to 12 months
Cohort 2 & 3: Proportion of Patients Achieving a New WHO Motor Development Milestones Relative to Baseline
The WHO Multicenter Growth Reference Study performance criteria is being utilized to assess the World Health Organization (WHO) motor development milestones of patients with Type 2 and nonambulatory Type 3 SMA enrolled in Cohort 2 and Cohort 3 relative to baseline. The WHO milestone assessment consists of six items which were selected because they have been considered to be universal, fundamental, and simple to test and evaluate, they include 1) sitting without support, 2) hands and knees crawling, 3) standing with assistance, 4) walking with assistance, 5) standing alone, and 6) walking without assistance. Each item is recorded as 1 (unable), 2 (refusal), 3 (Yes) or 9 (did not test). The number of 3s was counted as the final score. The minimum was 0, which means no motor milestones were achieved; the maximum was 6, which means all 6 milestones were achieved.
Time frame: Baseline to 12 months
Cohort 2 & 3: Proportion of Patients Achieving Various Magnitudes of Change in RULM Score From Baseline
The RULM is a 20 item assessment of upper limb function in nonambulatory patients with SMA that was performed for patients who were 30 months of age or older at baseline. The 19 scored items assess functions that relate to everyday life, such as pressing a button and picking up a token; these items are scored 0, 1, or 2, where 0 denotes unable, 1 denotes able with modification, and 2 denotes able with no modification. The maximum score achievable is 37.
Time frame: Baseline to 12 months
| Milestone | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy | Cohort 2 | Cohort 3 - Low Dose | Cohort 3 - High Dose |
|---|---|---|---|---|---|
| Started | 11 | 12 | 15 | 10 | 10 |
| Completed | 6 | 10 | 13 | 10 | 10 |
| Not completed | 5 | 2 | 2 | 0 | 0 |
The Revised Hammersmith Scale (RHS) is a 36 item clinical assessment of physical abilities in patients with Type 2 SMA and ambulatory or nonambulatory patients with Type 3 SMA. For the ambulatory Type 3 patients 5-21 years of age in Cohort 1 (N=23), the primary endpoint was the change from baseline in RHS total score at month 12. The RHS has a minimum achievable score of 0 and a maximum achievable score of 69. The RHS includes 33 items that are graded on a scale of 0, 1, 2, where 0 denotes the lowest level and 2 denotes the highest level of ability/function. The remaining 3 items are scored 0 or 1, where 0 denotes an inability and 1 denotes an ability to achieve. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement.
| score on a scale | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy |
|---|---|---|
| Cohort 1: Change From Baseline in the Revised Hammersmith Scale (RHS) Total Score at Day 364 (Visit 15) [Month 12] | -0.1 ± 5.01 | 0.0 ± 2.56 |
Cohort 2: For the nonambulatory Type 2 and Type 3 patients 5-21 years of age in Cohort 2 (N=15), the primary efficacy endpoint was the change from baseline in HFMSE total score at month 12. Cohort 3: For the nonambulatory Type 2 patients ≥2 years of age in Cohort 3 (N=20), the primary efficacy endpoint was the change from baseline in HFMSE total score at month 12. The Hammersmith Functional Motor Scale Expanded (HFMSE) assesses the physical abilities of patients with Type 2 and Type 3 SMA comprises 33 items graded on a scale of 0, 1, or 2, where 0 denotes unable, 1 denotes performed with modification or adaptation, and 2 denotes performed without modification or adaptation.
| score on a scale | Cohort 2 | Cohort 3 - Low Dose | Cohort 3 - High Dose |
|---|---|---|---|
| Cohort 2 and Cohort 3: Change From Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) Total Score at Day 364 (Visit 15) [Month 12] | 0.6 ± 3.5 | 5.3 ± 8.93 | 7.1 ± 6.42 |
The Revised Hammersmith Scale (RHS) is a 36 item clinical assessment of physical abilities in patients with Type 2 SMA and ambulatory or nonambulatory patients with Type 3 SMA; it has a maximum achievable score of 69. The RHS includes 33 items that are graded on a scale of 0, 1, 2, where 0 denotes the lowest level and 2 denotes the highest level of ability/function. The remaining 3 items are scored 0 or 1, where 0 denotes an inability and 1 denotes an ability to achieve.
| Participants | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy |
|---|---|---|
| ≥5pt at Day 56 (V4) | 1 | 1 |
| ≥5pt at Day 112 (V6) | 1 | 1 |
| ≥5pt at Day 168 (V8) | 2 | 1 |
| ≥5pt Month 12 Endpoint | 1 | 0 |
| ≥3pt at Day 56 (V4) | 3 | 3 |
| ≥3pt at Day 112 (V6) | 1 | 2 |
| ≥3pt at Day 168 (V8) | 4 | 1 |
| ≥3pt at Month 12 Endpoint | 3 | 3 |
| ≥1pt at Day 56 (V4) | 8 | 8 |
| ≥1pt at Day 112 (V6) | 3 | 5 |
| ≥1pt at Day 168 (V8) | 7 | 4 |
| ≥1pt at Month 12 Endpoint | 6 | 5 |
| No Change at Day 56 (V4) | 1 | 1 |
| No Change at Day 112 (V6) | 5 | 1 |
| No Change at Day 168 (V8) | 1 | 5 |
| No Change at Month 12 Endpoint | 0 | 2 |
| Decrease at Day 56 (V4) | 2 | 3 |
| Decrease at Day 112 (V6) | 2 | 5 |
| Decrease at Day 168 (V8) | 3 | 2 |
| Decrease at Month 12 Endpoint | 5 | 5 |
The Revised Hammersmith Scale (RHS) is a 36 item clinical assessment of physical abilities in patients with Type 2 SMA and ambulatory or nonambulatory patients with Type 3 SMA; it has a maximum achievable score of 69. The RHS includes 33 items that are graded on a scale of 0, 1, 2, where 0 denotes the lowest level and 2 denotes the highest level of ability/function. The remaining 3 items are scored 0 or 1, where 0 denotes an inability and 1 denotes an ability to achieve.
| Participants | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy |
|---|---|---|
| ≥3pt increase | 3 | 3 |
| ≥1pt increase | 6 | 5 |
| No Change | 0 | 2 |
| Decrease | 5 | 5 |
6-Minute Walk Test The 6-Minute Walk Test (6MWT) is an assessment of exercise capacity and fatigue used for ambulatory patients with later-onset SMA who are directed to walk along a 25 meter course as fast as possible over 6 minutes.
| Meters | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy |
|---|---|---|
| Cohort 1: Change From Baseline in 6-Minute Walk Test (6MWT) | -20.6 ± 44.96 | 11.0 ± 33.67 |
The 30-Second Sit-to-Stand Test is an assessment of functional lower-limb strength that measures the maximal number of times a patient can transition from sitting to standing in 30 seconds.
| Stands | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy |
|---|---|---|
| Cohort 1: Change From Baseline in 30-Second Sit-to-Stand | -0.6 ± 1.63 | -0.2 ± 1.95 |
The 10 Meter Walk/Run test is an enhanced function of the RHS used for ambulatory patients with Type 3 SMA. It is a measure of the time taken to walk/run 10 meters. The time to perform is summarized only for patients able to complete the RHS 10-meter walk/run item.
| Seconds | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy |
|---|---|---|
| Cohort 1: Change From Baseline in 10-Meter Walk/Run (From RHS) | 0.1 ± 0.32 | 0.9 ± 3.32 |
The timed rise from floor test is an enhanced function of the RHS used for ambulatory patients with Type 3 SMA. It is a measure of the time taken to rise to standing from the floor. The time to rise from floor is summarized only for patients able to complete the RHS rise from floor item.
| Seconds | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy |
|---|---|---|
| Cohort 1: Change From Baseline in Timed Rise From Floor (From RHS) | 0.6 ± 1.75 | -0.6 ± 1.43 |
The Hammersmith Functional Motor Scale Expanded (HFMSE) assesses the physical abilities of patients with Type 2 and Type 3 SMA comprises 33 items graded on a scale of 0, 1, or 2, where 0 denotes unable, 1 denotes performed with modification or adaptation, and 2 denotes performed without modification or adaptation.
| Participants | Cohort 2 | Cohort 3 - Low Dose | Cohort 3 - High Dose |
|---|---|---|---|
| ≥5pt at Day 56 (V4) | 1 | 0 | 3 |
| ≥5pt at Day 112 (V6) | 1 | 2 | 5 |
| ≥5pt at Day 168 (V8) | 1 | 3 | 4 |
| ≥5pt at Month 12 Endpoint | 2 | 5 | 5 |
| ≥3pt at Day 56 (V4) | 1 | 4 | 5 |
| ≥3pt at Day 112 (V6) | 2 | 3 | 5 |
| ≥3pt at Day 168 (V8) | 2 | 4 | 5 |
| ≥3pt at Month 12 Endpoint | 4 | 5 | 5 |
| ≥1pt at Day 56 (V4) | 4 | 6 | 8 |
| ≥1pt at Day 112 (V6) | 6 | 5 | 9 |
| ≥1pt at Day 168 (V8) | 10 | 5 | 8 |
| ≥1pt at Month 12 Endpoint | 9 | 7 | 7 |
| No Change at Day 56 (V4) | 4 | 1 | 1 |
| No Change at Day 112 (V6) | 5 | 2 | 1 |
| No Change at Day 168 (V8) | 1 | 1 | 0 |
| No Change at Month 12 Endpoint | 1 | 0 | 0 |
| Decrease at Day 56 (V4) | 7 | 3 | 1 |
| Decrease at Day 112 (V6) | 3 | 3 | 0 |
| Decrease at Day 168 (V8) | 3 | 1 | 0 |
| Decrease at Month 12 Endpoint | 4 | 2 | 1 |
The Hammersmith Functional Motor Scale Expanded (HFMSE) assesses the physical abilities of patients with Type 2 and Type 3 SMA comprises 33 items graded on a scale of 0, 1, or 2, where 0 denotes unable, 1 denotes performed with modification or adaptation, and 2 denotes performed without modification or adaptation.
| Participants | Cohort 2 | Cohort 3 - Low Dose | Cohort 3 - High Dose |
|---|---|---|---|
| ≥3pt increase | 4 | 5 | 5 |
| ≥1pt increase | 9 | 7 | 7 |
| No Change | 1 | 0 | 0 |
| Decrease | 4 | 2 | 1 |
The RULM is a 20 item assessment of upper limb function in nonambulatory patients with SMA that was performed for patients who were 30 months of age or older at baseline. The 19 scored items assess functions that relate to everyday life, such as pressing a button and picking up a token; these items are scored 0, 1, or 2, where 0 denotes unable, 1 denotes able with modification, and 2 denotes able with no modification. The maximum score achievable is 37.
| Score on scale | Cohort 2 | Cohort 3 - Low Dose | Cohort 3 - High Dose |
|---|---|---|---|
| Cohort 2 & 3: Change in Baseline in Revised Upper Limb Module (RULM) Total Score | 1.2 ± 2.99 | 0.9 ± 2.62 | 1 ± 2.94 |
The WHO Multicenter Growth Reference Study performance criteria is being utilized to assess the World Health Organization (WHO) motor development milestones of patients with Type 2 and nonambulatory Type 3 SMA enrolled in Cohort 2 and Cohort 3 relative to baseline. The WHO milestone assessment consists of six items which were selected because they have been considered to be universal, fundamental, and simple to test and evaluate, they include 1) sitting without support, 2) hands and knees crawling, 3) standing with assistance, 4) walking with assistance, 5) standing alone, and 6) walking without assistance. Each item is recorded as 1 (unable), 2 (refusal), 3 (Yes) or 9 (did not test). The number of 3s was counted as the final score. The minimum was 0, which means no motor milestones were achieved; the maximum was 6, which means all 6 milestones were achieved.
| Participants | Cohort 2 | Cohort 3 - Low Dose | Cohort 3 - High Dose |
|---|---|---|---|
| ≥2pt increase | 1 | 0 | 1 |
| ≥1pt increase | 3 | 1 | 1 |
| No Change | 11 | 7 | 6 |
| Decrease | 0 | 1 | 1 |
The RULM is a 20 item assessment of upper limb function in nonambulatory patients with SMA that was performed for patients who were 30 months of age or older at baseline. The 19 scored items assess functions that relate to everyday life, such as pressing a button and picking up a token; these items are scored 0, 1, or 2, where 0 denotes unable, 1 denotes able with modification, and 2 denotes able with no modification. The maximum score achievable is 37.
| Participants | Cohort 2 | Cohort 3 - Low Dose | Cohort 3 - High Dose |
|---|---|---|---|
| ≥2pt increase | 5 | 3 | 2 |
| ≥1pt increase | 8 | 3 | 3 |
| No change | 1 | 3 | 2 |
| Decrease | 5 | 3 | 2 |
Collected over Day 0 (Visit 1) to 48 months (Visit EC14). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 - Monotherapy | 0/11 (0%) | 4/11 (36.4%) | 11/11 (100%) |
| Cohort 1 - Dual Therapy | 0/12 (0%) | 4/12 (33.3%) | 11/12 (91.7%) |
| Cohort 2 | 0/15 (0%) | 9/15 (60%) | 15/15 (100%) |
| Cohort 3 - Low Dose | 0/10 (0%) | 6/10 (60%) | 10/10 (100%) |
| Cohort 3 - High Dose | 0/10 (0%) | 5/10 (50%) | 9/10 (90%) |
| Event | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy | Cohort 2 | Cohort 3 - Low Dose | Cohort 3 - High Dose |
|---|---|---|---|---|---|
| Scoliosis surgerySurgical and medical procedures | 0/11 | 1/12 | 5/15 | 0/10 | 1/10 |
| PneumoniaInfections and infestations | 0/11 | 0/12 | 0/15 | 1/10 | 2/10 |
| ScoliosisMusculoskeletal and connective tissue disorders | 1/11 | 0/12 | 3/15 | 0/10 | 1/10 |
| Gait InabilityGeneral disorders | 2/11 | 0/12 | 0/15 | 0/10 | 0/10 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/11 | 0/12 | 0/15 | 0/10 | 1/10 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/11 | 0/12 | 0/15 | 0/10 | 1/10 |
| Tonsillar HypertrophyRespiratory, thoracic and mediastinal disorders | 0/11 | 0/12 | 0/15 | 1/10 | 0/10 |
| VomitingGastrointestinal disorders | 1/11 | 0/12 | 0/15 | 1/10 | 0/10 |
| Respiratory syncytial virus infectionInfections and infestations | 0/11 | 0/12 | 1/15 | 0/10 | 1/10 |
| Rhinovirus infectionInfections and infestations | 0/11 | 0/12 | 0/15 | 1/10 | 0/10 |
| Event | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy | Cohort 2 | Cohort 3 - Low Dose | Cohort 3 - High Dose |
|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 2/11 | 5/12 | 6/15 | 4/10 | 9/10 |
| VomitingGastrointestinal disorders | 1/11 | 1/12 | 2/15 | 6/10 | 8/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/11 | 5/12 | 4/15 | 5/10 | 7/10 |
| HeadacheNervous system disorders | 7/11 | 5/12 | 5/15 | 4/10 | 3/10 |
| NasopharyngitisInfections and infestations | 4/11 | 1/12 | 6/15 | 6/10 | 5/10 |
| COVID-19Infections and infestations | 5/11 | 3/12 | 6/15 | 6/10 | 6/10 |
| Upper respiratory tract infectionInfections and infestations | 5/11 | 5/12 | 5/15 | 4/10 | 5/10 |
| NauseaGastrointestinal disorders | 4/11 | 3/12 | 3/15 | 5/10 | 3/10 |
| FallInjury, poisoning and procedural complications | 5/11 | 6/12 | 1/15 | 2/10 | 1/10 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 2/11 | 1/12 | 2/15 | 2/10 | 4/10 |
Intent-to-Treat (ITT) Set: All participants who were enrolled/randomized and received at least 1 dose of study drug.
| Age, Continuous(Years) | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy | Cohort 2 | Cohort 3 - Low Dose | Cohort 3 - High Dose | Total |
|---|---|---|---|---|---|---|
| Mean | 12.1 (7 to 19) | 13.1 (7 to 21) | 11.7 (8 to 19) | 4.1 (2 to 6) | 3.8 (2 to 6) | 9.67 (2 to 21) |
| Sex: Female, Male(Participants) | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy | Cohort 2 | Cohort 3 - Low Dose | Cohort 3 - High Dose | Total |
|---|---|---|---|---|---|---|
| Female | 8 | 7 | 8 | 3 | 5 | 31 |
| Male | 3 | 5 | 7 | 7 | 5 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy | Cohort 2 | Cohort 3 - Low Dose | Cohort 3 - High Dose | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 | 0 | 1 | 5 |
| Not Hispanic or Latino | 11 | 10 | 13 | 10 | 9 | 53 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 - Monotherapy | Cohort 1 - Dual Therapy | Cohort 2 | Cohort 3 - Low Dose | Cohort 3 - High Dose | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 6 | 0 | 2 | 0 | 1 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 1 | 2 |
| White | 5 | 12 | 12 | 10 | 8 | 47 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Jan 2021, 20 months.
Results were first posted in Nov 2022, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apitegromab
Spinal Muscular Atrophies of Childhood →
Scholar Rock, Inc.